Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody

Allan Flyvbjerg, Frederlk Dagnæs-Hansen, An S. De Vriese, Bieke F. Schrijvers, Ronald Tilton, Ruth Rasch

Research output: Contribution to journalArticle

253 Citations (Scopus)

Abstract

Diabetic nephropathy in type 2 diabetic patients is a frequent complication associated with increased morbidity and mortality. Various growth factors and cytokines have been implicated in the pathogenesis of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To explore a role for VEGF in renal changes in type 2 diabetes, we examined the renal effects of a neutralizing murine VEGF antibody in the diabetic db/db mouse, a model of obese type 2 diabetes. One group of db/db mice was treated for 2 months with a VEGF antibody, while another db/db group was treated for the same period with an isotype-matched irrelevant IgG. A third group consisting of nondiabetic db/+ mice was treated with the same isotype-matched IgG for 2 months. Placebo-treated db/db mice showed a pronounced increase in kidney weight, glomerular volume, basement membrane thickness (BMT), total mesangial volume, urinary albumin excretion (UAE), and creatinine clearance (CrCl) when compared with nondiabetic controls. In VEGF antibody-treated db/db mice, increases in kidney weight, glomerular volume, BMT, and UAE were attenuated, whereas the increase in CrCl was abolished. VEGF antibody administration tended to reduce expansion in total mesangial volume. These effects in diabetic animals were seen without impact on body weight, blood glucose, insulin levels, or food consumption. In conclusion, chronic inhibition of VEGF in db/db mice ameliorates the diabetic renal changes seen in type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)3090-3094
Number of pages5
JournalDiabetes
Volume51
Issue number10
StatePublished - Oct 1 2002
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Kidney
Antibodies
Type 2 Diabetes Mellitus
Glomerular Basement Membrane
Diabetic Nephropathies
Albumins
Creatinine
Immunoglobulin G
Weights and Measures
Blood Glucose
Intercellular Signaling Peptides and Proteins
Placebos
Body Weight
Insulin
Cytokines
Morbidity
Food
Mortality

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Flyvbjerg, A., Dagnæs-Hansen, F., De Vriese, A. S., Schrijvers, B. F., Tilton, R., & Rasch, R. (2002). Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes, 51(10), 3090-3094.

Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. / Flyvbjerg, Allan; Dagnæs-Hansen, Frederlk; De Vriese, An S.; Schrijvers, Bieke F.; Tilton, Ronald; Rasch, Ruth.

In: Diabetes, Vol. 51, No. 10, 01.10.2002, p. 3090-3094.

Research output: Contribution to journalArticle

Flyvbjerg, A, Dagnæs-Hansen, F, De Vriese, AS, Schrijvers, BF, Tilton, R & Rasch, R 2002, 'Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody', Diabetes, vol. 51, no. 10, pp. 3090-3094.
Flyvbjerg A, Dagnæs-Hansen F, De Vriese AS, Schrijvers BF, Tilton R, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002 Oct 1;51(10):3090-3094.
Flyvbjerg, Allan ; Dagnæs-Hansen, Frederlk ; De Vriese, An S. ; Schrijvers, Bieke F. ; Tilton, Ronald ; Rasch, Ruth. / Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. In: Diabetes. 2002 ; Vol. 51, No. 10. pp. 3090-3094.
@article{43deb5a9ece148cd9d786466d9f1d00b,
title = "Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody",
abstract = "Diabetic nephropathy in type 2 diabetic patients is a frequent complication associated with increased morbidity and mortality. Various growth factors and cytokines have been implicated in the pathogenesis of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To explore a role for VEGF in renal changes in type 2 diabetes, we examined the renal effects of a neutralizing murine VEGF antibody in the diabetic db/db mouse, a model of obese type 2 diabetes. One group of db/db mice was treated for 2 months with a VEGF antibody, while another db/db group was treated for the same period with an isotype-matched irrelevant IgG. A third group consisting of nondiabetic db/+ mice was treated with the same isotype-matched IgG for 2 months. Placebo-treated db/db mice showed a pronounced increase in kidney weight, glomerular volume, basement membrane thickness (BMT), total mesangial volume, urinary albumin excretion (UAE), and creatinine clearance (CrCl) when compared with nondiabetic controls. In VEGF antibody-treated db/db mice, increases in kidney weight, glomerular volume, BMT, and UAE were attenuated, whereas the increase in CrCl was abolished. VEGF antibody administration tended to reduce expansion in total mesangial volume. These effects in diabetic animals were seen without impact on body weight, blood glucose, insulin levels, or food consumption. In conclusion, chronic inhibition of VEGF in db/db mice ameliorates the diabetic renal changes seen in type 2 diabetes.",
author = "Allan Flyvbjerg and Frederlk Dagn{\ae}s-Hansen and {De Vriese}, {An S.} and Schrijvers, {Bieke F.} and Ronald Tilton and Ruth Rasch",
year = "2002",
month = "10",
day = "1",
language = "English (US)",
volume = "51",
pages = "3090--3094",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody

AU - Flyvbjerg, Allan

AU - Dagnæs-Hansen, Frederlk

AU - De Vriese, An S.

AU - Schrijvers, Bieke F.

AU - Tilton, Ronald

AU - Rasch, Ruth

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Diabetic nephropathy in type 2 diabetic patients is a frequent complication associated with increased morbidity and mortality. Various growth factors and cytokines have been implicated in the pathogenesis of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To explore a role for VEGF in renal changes in type 2 diabetes, we examined the renal effects of a neutralizing murine VEGF antibody in the diabetic db/db mouse, a model of obese type 2 diabetes. One group of db/db mice was treated for 2 months with a VEGF antibody, while another db/db group was treated for the same period with an isotype-matched irrelevant IgG. A third group consisting of nondiabetic db/+ mice was treated with the same isotype-matched IgG for 2 months. Placebo-treated db/db mice showed a pronounced increase in kidney weight, glomerular volume, basement membrane thickness (BMT), total mesangial volume, urinary albumin excretion (UAE), and creatinine clearance (CrCl) when compared with nondiabetic controls. In VEGF antibody-treated db/db mice, increases in kidney weight, glomerular volume, BMT, and UAE were attenuated, whereas the increase in CrCl was abolished. VEGF antibody administration tended to reduce expansion in total mesangial volume. These effects in diabetic animals were seen without impact on body weight, blood glucose, insulin levels, or food consumption. In conclusion, chronic inhibition of VEGF in db/db mice ameliorates the diabetic renal changes seen in type 2 diabetes.

AB - Diabetic nephropathy in type 2 diabetic patients is a frequent complication associated with increased morbidity and mortality. Various growth factors and cytokines have been implicated in the pathogenesis of diabetic kidney disease, including vascular endothelial growth factor (VEGF). To explore a role for VEGF in renal changes in type 2 diabetes, we examined the renal effects of a neutralizing murine VEGF antibody in the diabetic db/db mouse, a model of obese type 2 diabetes. One group of db/db mice was treated for 2 months with a VEGF antibody, while another db/db group was treated for the same period with an isotype-matched irrelevant IgG. A third group consisting of nondiabetic db/+ mice was treated with the same isotype-matched IgG for 2 months. Placebo-treated db/db mice showed a pronounced increase in kidney weight, glomerular volume, basement membrane thickness (BMT), total mesangial volume, urinary albumin excretion (UAE), and creatinine clearance (CrCl) when compared with nondiabetic controls. In VEGF antibody-treated db/db mice, increases in kidney weight, glomerular volume, BMT, and UAE were attenuated, whereas the increase in CrCl was abolished. VEGF antibody administration tended to reduce expansion in total mesangial volume. These effects in diabetic animals were seen without impact on body weight, blood glucose, insulin levels, or food consumption. In conclusion, chronic inhibition of VEGF in db/db mice ameliorates the diabetic renal changes seen in type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0036789207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036789207&partnerID=8YFLogxK

M3 - Article

C2 - 12351452

AN - SCOPUS:0036789207

VL - 51

SP - 3090

EP - 3094

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -